Skip to main content

Table 1 Evidence suggesting the beneficial effects of MSCs on the AKI-CKD transition

From: Current understanding of the administration of mesenchymal stem cells in acute kidney injury to chronic kidney disease transition: a review with a focus on preclinical models

ReferencesYearAnimalModelRenal outcomes
Zhu et al. [84]2017MiceUnilateral I/R injury↓Fibrosis; ↑kidney weight and size; ↓α-SMA and collagen-I; ↓TGF-β1/Smad3
Masoud et al. [85]2012RatsUnilateral I/R injury↓Fibrosis
Semedo et al. [86]2010MiceUnilateral I/R injury↓Fibrosis; ↓proteinuria; ↑renal areas; ↓a-SMA, vimentin, and FSP-1
Gatti et al. [88]2011RatsUnilateral I/R injury with contralateral nephrectomy↑Renal function; ↓fibrosis; ↓proteinuria
Du et al. [90]2012RatsUnilateral I/R injury with contralateral nephrectomy↑Renal function; ↓fibrosis
Zou et al. [89]2014RatsUnilateral I/R injury with contralateral nephrectomy↑Renal function; ↓fibrosis; ↓α-SMA
Alfarano et al. [91]2012RatsUnilateral I/R injury with contralateral nephrectomy↑Renal function; ↓fibrosis and tubular dilation; ↓α-SMA and MMP2
Zhou et al. [93]2016RatsUnilateral I/R injury with contralateral nephrectomy↑Renal function; ↓fibrosis; ↓α-SMA; ↓microvascular rarefaction
Tögel et al. [94]2009RatsBilateral I/R injury↑Renal function; ↓fibrosis; ↓PAI-1 and TGF-β
Du et al. [96]2013RatsBilateral I/R injury↓Fibrosis
Rodrigues et al. [97]2017RatsBilateral I/R injury↑Renal function; ↓FENa; ↓urinary concentrating defect; ↓renal damage score; ↓senescence
  1. I/R ischemia/reperfusion, α-SMA α-smooth muscle actin, MMP2 matrix metalloproteinase 2, FSP-1 fibroblast specific protein-1, PAI-1 plasminogen activator inhibitor-1